Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Steroid 5-alpha-reductase (EC 220.127.116.11) catalyzes the conversion of testosterone into the more potent androgen, dihydrotestosterone (DHT). Additionally we are shipping SRD5A1 Kits (16) and SRD5A1 Proteins (3) and many more products for this protein.
Showing 10 out of 53 products:
Human Polyclonal SRD5A1 Primary Antibody for IHC (p), IHC - ABIN250339
Iczkowski, Qiu, Qian, Somerville, Rittmaster, Andriole, Bostwick: The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. in Urology 2005
Show all 8 references for ABIN250339
Human Polyclonal SRD5A1 Primary Antibody for WB - ABIN520464
Park, Aizawa, Iemitsu, Sato, Akimoto, Agata, Maeda, Ezawa, Omi: DHEA administration activates local bioactive androgen metabolism in cancellous site of tibia of ovariectomized rats. in Calcified tissue international 2011
Show all 2 references for ABIN520464
the Srd5a1 gene modulates ethanol consumption in a sex-dependent manner that is also contingent upon ethanol access condition and concentration
deletion of the Srd5a1 gene significantly decreased ethanol's anxiolytic effect in female mice, and chronic ethanol withdrawal severity was lower in female versus male mice
transcription of srd5a1 in brain is regulated by environmental factor-induced cytosine methylation in the promoter region.
The effects of deficiency or inhibition of S5AR1 on the risk of liver disease and insulin (show INS Antibodies) resistance in male rats and mice are reported.
Thus, 5alpha-reductase may be required for the estrous cycle variations in affective behavior and 3alpha,5alpha-THP (show UMOD Antibodies) levels of female mice.
results suggest that local steroid 5 alpha-reductase 1 messenger RNA expression in Withdrawal Seizure-Prone mouse brain may not change in parallel with local allopregnanolone content or withdrawal severity
The aim of the present study was to investigate the role of 5alpha-reductase type 1 for bone mass using Srd5a1-/- mice.
This study evaluates 5alpha-R type I and 3alpha-HSD (show DHRS9 Antibodies) mRNA expression level in mouse brain by using in situ hybridization.
Data suggests that in male mice after social isolation, expression of Srd5a1 mRNA is specifically down-regulated in glutamatergic pyramidal neurons. In socially isolated mice, this down-regulation may account for the appearance of behavioral disorders.
SRD5A1 small-interfering RNA knockdown led to significant increase in progesterone receptor (show PGR Antibodies)-B nuclear import, ectopic, whereas SRD5A1 overexpression resulted in remarkable inhibition of nuclear progesterone receptor (show PGR Antibodies)-B in P4-treated cells. Repression of SRD5A1 activated progesterone receptor (show PGR Antibodies)-B responsive gene, whereas overexpression of SRD5A1 possessed an inhibitory effect.
the genotypic distribution of 22 single nucleotide polymorphisms in SRD5A1 and SRD5A2 (show SRD5A2 Antibodies) in a set of Spanish prostate cancer patients, were evaluated.
A total of 2 SNPs in SRD5A1-rs3822430 and rs1691053-were associated with prostate-specific antigen (show KLK3 Antibodies) level at diagnosis.
In model cell lines of endometrial cancer, AKR1C2 (show AKR1C2 Antibodies) and SRD5A1 have crucial roles in progesterone metabolism.
SRD5A1 rs166050C risk variant was associated with greater prostatic exposure to androsterone
Significantly higher levels of SRD5A1, AKR1C2 (show AKR1C2 Antibodies), AKR1C3 (show AKR1C3 Antibodies), and HSD17B10 (show HSD17B10 Antibodies) mRNA were however found in bone metastases than in non-malignant and/or malignant prostate tissue
SRD5A1 and SRD5A2 (show SRD5A2 Antibodies) single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment.
Different effects were seen for progesterone, which significantly decreased SRD5A1 protein levels.
Postmenopausal breast cancer risk associated with combined therapy may be modified by genetic variation in SRD5A1
Based on a limited selection of gene variants, no involvement of SRD5A1, SRD5A2 (show SRD5A2 Antibodies), ESR1 (show ESR1 Antibodies), ESR2 (show ESR2 Antibodies) or PGR (show PGR Antibodies) in female pattern hair loss is evident.
Steroid 5-alpha-reductase (EC 18.104.22.168) catalyzes the conversion of testosterone into the more potent androgen, dihydrotestosterone (DHT). Also see SRD5A2 (MIM 607306).
, 3-oxo-5-alpha-steroid 4-dehydrogenase 1
, SR type 1
, steroid 5-alpha-reductase 1
, type 1 5alpha-reductase
, 3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1
, 5-alpha reductase
, steroid 5-alpha-reductase type I
, steroid 5 alpha-reductase 1
, prostatic steroid 5-alpha-reductase type I
, 3-oxo-5-alpha-steroid 4-dehydrogenase 1-like